Rabacfosadine succinate
Code | Size | Price |
---|
TAR-T24702-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24702-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T24702-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Rabacfosadine succinate is the acyclic nucleoside phosphonate PMEG double prodrug.
CAS:
1431856-99-3
Formula:
C25H41N8O10P
Molecular Weight:
644.62
Purity:
0.98
SMILES:
O=P(N[C@@H](C)C(OCC)=O)(N[C@@H](C)C(OCC)=O)COCCN1C=NC2=C(NC3CC3)N=C(N)N=C12
References
1. De Clercq E. Tanovea? for the treatment of lymphoma in dogs. Biochem Pharmacol. 2018 May 17;154:265-269. doi: 10.1016/j.bcp.2018.05.010. [Epub ahead of print] Review. PubMed PMID: 29778492.
2. Saba CF, Vickery KR, Clifford CA, Burgess KE, Phillips B, Vail DM, Wright ZM, Morges MA, Fan TM, Thamm DH. Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses. Vet Comp Oncol. 2018 Mar;16(1):E76-E82. doi: 10.1111/vco.12337. Epub 2017 Sep 11. PubMed PMID: 28891260.
3. Thamm DH, Vail DM, Post GS, Fan TM, Phillips BS, Axiak-Bechtel S, Elmslie RS, Klein MK, Ruslander DA. Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Na?ve Canine Multicentric Lymphoma. J Vet Intern Med. 2017 May;31(3):872-878. doi: 10.1111/jvim.14700. Epub 2017 Apr 3. PubMed PMID: 28370378; PubMed Central PMCID: PMC5435064.
4. Morges MA, Burton JH, Saba CF, Vail DM, Burgess KE, Thamm DH. Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. J Vet Intern Med. 2014 Sep-Oct;28(5):1569-74. doi: 10.1111/jvim.12429. PubMed PMID: 25274443; PubMed Central PMCID: PMC4895598.